source
- Analysts focus on three programs in big year for Bristol MyersWall Street’s expectations for Bristol Myers Squibb’s upcoming slate of data readouts are reaching a fever pitch. Analysts lobbed questions regarding at least half a dozen trial results expected by…Endpoints · 3mo ago↗ source
- STAT+: Hinge has a new FDA-cleared migraine deviceIn this edition of STAT Health Tech: FDA's plan to use AI to speed up trials, Hinge's new migraine device, and boosting cancer screening with texts.STAT · 3mo ago↗ source
- Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launchA strong performance from Mounjaro overseas boosted Lilly’s results, and the company raised its guidance for the year for both profit and revenue.BioPharma Dive · 3mo ago